KORU MEDICAL SYSTEMS INC (KRMD) Stock Fundamental Analysis
USA - NASDAQ:KRMD - US7599101026 - Common Stock
3.9 USD
-0.05 (-1.27%)
3.9 USD
0 (0%)
Taking everything into account, KRMD scores 3 out of 10 in our fundamental rating. KRMD was compared to 189 industry peers in the Health Care Equipment & Supplies industry. The financial health of KRMD is average, but there are quite some concerns on its profitability. KRMD is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year KRMD has reported negative net income.
KRMD had a negative operating cash flow in the past year.
In the past 5 years KRMD always reported negative net income.
KRMD had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
With a Return On Assets value of -17.69%, KRMD perfoms like the industry average, outperforming 51.85% of the companies in the same industry.
Looking at the Return On Equity, with a value of -27.32%, KRMD is in line with its industry, outperforming 57.14% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.69% | ||
| ROE | -27.32% | ||
| ROIC | N/A |
ROA(3y)-30.34%
ROA(5y)-21.02%
ROE(3y)-43.74%
ROE(5y)-29.41%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 63.15%, KRMD is in the better half of the industry, outperforming 65.61% of the companies in the same industry.
KRMD's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for KRMD so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.15% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.65%
GM growth 5Y-0.23%
2. Health
2.1 Basic Checks
KRMD does not have a ROIC to compare to the WACC, probably because it is not profitable.
KRMD has more shares outstanding than it did 1 year ago.
KRMD has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, KRMD has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 11.86 indicates that KRMD is not in any danger for bankruptcy at the moment.
KRMD's Altman-Z score of 11.86 is amongst the best of the industry. KRMD outperforms 91.01% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that KRMD is not too dependend on debt financing.
The Debt to Equity ratio of KRMD (0.01) is better than 71.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Altman-Z | 11.86 |
ROIC/WACCN/A
WACC8.72%
2.3 Liquidity
A Current Ratio of 2.91 indicates that KRMD has no problem at all paying its short term obligations.
KRMD's Current ratio of 2.91 is in line compared to the rest of the industry. KRMD outperforms 58.73% of its industry peers.
A Quick Ratio of 2.25 indicates that KRMD has no problem at all paying its short term obligations.
KRMD has a Quick ratio of 2.25. This is comparable to the rest of the industry: KRMD outperforms 56.61% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.25 |
3. Growth
3.1 Past
KRMD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 20.00%, which is quite impressive.
The Revenue has grown by 19.57% in the past year. This is quite good.
The Revenue has been growing slightly by 7.76% on average over the past years.
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
Revenue 1Y (TTM)19.57%
Revenue growth 3Y12.72%
Revenue growth 5Y7.76%
Sales Q2Q%20.94%
3.2 Future
The Earnings Per Share is expected to grow by 30.14% on average over the next years. This is a very strong growth
The Revenue is expected to grow by 16.30% on average over the next years. This is quite good.
EPS Next Y18.4%
EPS Next 2Y32.48%
EPS Next 3Y30.14%
EPS Next 5YN/A
Revenue Next Year18.53%
Revenue Next 2Y17.44%
Revenue Next 3Y16.3%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
KRMD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for KRMD. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as KRMD's earnings are expected to grow with 30.14% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y32.48%
EPS Next 3Y30.14%
5. Dividend
5.1 Amount
No dividends for KRMD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
3.9
-0.05 (-1.27%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners55.68%
Inst Owner ChangeN/A
Ins Owners8.29%
Ins Owner Change1.57%
Market Cap180.30M
Revenue(TTM)36.85M
Net Income(TTM)-4515000
Analysts80
Price Target5.71 (46.41%)
Short Float %2%
Short Ratio10.4
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)62.29%
Min EPS beat(2)24.59%
Max EPS beat(2)100%
EPS beat(4)4
Avg EPS beat(4)37.77%
Min EPS beat(4)3.88%
Max EPS beat(4)100%
EPS beat(8)8
Avg EPS beat(8)40.05%
EPS beat(12)12
Avg EPS beat(12)34.3%
EPS beat(16)15
Avg EPS beat(16)29.18%
Revenue beat(2)2
Avg Revenue beat(2)6.08%
Min Revenue beat(2)5.66%
Max Revenue beat(2)6.5%
Revenue beat(4)3
Avg Revenue beat(4)3.5%
Min Revenue beat(4)-2.56%
Max Revenue beat(4)6.5%
Revenue beat(8)6
Avg Revenue beat(8)2.35%
Revenue beat(12)7
Avg Revenue beat(12)1.68%
Revenue beat(16)11
Avg Revenue beat(16)2.34%
PT rev (1m)0%
PT rev (3m)1.82%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-75%
EPS NY rev (1m)0%
EPS NY rev (3m)-3.23%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.59%
Revenue NY rev (1m)0%
Revenue NY rev (3m)2.47%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 4.89 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 10.91 | ||
| P/tB | 11.39 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.08
EYN/A
EPS(NY)-0.02
Fwd EYN/A
FCF(TTM)-0.05
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.8
BVpS0.36
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -17.69% | ||
| ROE | -27.32% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 63.15% | ||
| FCFM | N/A |
ROA(3y)-30.34%
ROA(5y)-21.02%
ROE(3y)-43.74%
ROE(5y)-29.41%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.65%
GM growth 5Y-0.23%
F-Score5
Asset Turnover1.44
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 177.3% | ||
| Cap/Sales | 4.17% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.91 | ||
| Quick Ratio | 2.25 | ||
| Altman-Z | 11.86 |
F-Score5
WACC8.72%
ROIC/WACCN/A
Cap/Depr(3y)239.72%
Cap/Depr(5y)210.83%
Cap/Sales(3y)5.63%
Cap/Sales(5y)4.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)20%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%100%
EPS Next Y18.4%
EPS Next 2Y32.48%
EPS Next 3Y30.14%
EPS Next 5YN/A
Revenue 1Y (TTM)19.57%
Revenue growth 3Y12.72%
Revenue growth 5Y7.76%
Sales Q2Q%20.94%
Revenue Next Year18.53%
Revenue Next 2Y17.44%
Revenue Next 3Y16.3%
Revenue Next 5YN/A
EBIT growth 1Y32.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year95.4%
EBIT Next 3Y43.64%
EBIT Next 5YN/A
FCF growth 1Y67.58%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y87.78%
OCF growth 3YN/A
OCF growth 5YN/A
KORU MEDICAL SYSTEMS INC / KRMD FAQ
What is the ChartMill fundamental rating of KORU MEDICAL SYSTEMS INC (KRMD) stock?
ChartMill assigns a fundamental rating of 3 / 10 to KRMD.
What is the valuation status of KORU MEDICAL SYSTEMS INC (KRMD) stock?
ChartMill assigns a valuation rating of 1 / 10 to KORU MEDICAL SYSTEMS INC (KRMD). This can be considered as Overvalued.
Can you provide the profitability details for KORU MEDICAL SYSTEMS INC?
KORU MEDICAL SYSTEMS INC (KRMD) has a profitability rating of 1 / 10.
How financially healthy is KORU MEDICAL SYSTEMS INC?
The financial health rating of KORU MEDICAL SYSTEMS INC (KRMD) is 5 / 10.